---

Warfarin - Complete Pharmacological Profile

Mechanism of Action

The Vitamin K Cycle

1. Vitamin K-dependent clotting factors (II, VII, IX, X) and anticoagulant proteins (C and S) possess glutamic acid residues at their N-termini.
2. A posttranslational modification adds a carboxyl group to the gamma-carbon of these residues, generating gamma-carboxyglutamic acid (Gla). This is essential because it permits calcium-dependent binding to anionic phospholipid surfaces.
3. This gamma-carboxylation reaction is catalyzed by gamma-glutamyl carboxylase, which requires reduced vitamin K (vitamin K hydroquinone) as a cofactor.
4. During carboxylation, vitamin K hydroquinone is oxidized to vitamin K epoxide. The epoxide must then be reduced back to vitamin K by vitamin K epoxide reductase (VKORC1) to keep the cycle going.
5. Warfarin inhibits VKORC1, blocking the regeneration of active vitamin K. This depletes reduced vitamin K, impairing gamma-carboxylation, and results in the synthesis of nonfunctional prozymogens - partially carboxylated clotting proteins with little or no biological activity.

Stereochemistry & Pharmacokinetics

• Warfarin is a racemic mixture of R- and S-enantiomers.
• S-warfarin is 4x more potent than R-warfarin.
• S-warfarin is metabolized by CYP2C9; R-warfarin by CYP1A2 and CYP3A4.
• Oral bioavailability is nearly 100%; peak blood levels ~90 minutes after ingestion.
• Plasma half-life: 36-42 hours.

• 97% protein-bound (to albumin).

• Onset of action is delayed (4-5 days for full antithrombotic effect) because it requires depletion of already-circulating active clotting factors. The rate-limiting step is the fall in functional prothrombin (factor II, t½ = 72 hours) and factor X (t½ = 24 hours).
• Because of this delay, patients with active thrombosis need a bridging parenteral anticoagulant (heparin, LMWH, fondaparinux) for at least 5 days.

Genetic Pharmacology

• CYP2C9 variants (*2, *3): Reduce S-warfarin metabolism → lower dose requirements and higher bleeding risk.
• VKORC1 variants: Affect enzyme susceptibility to inhibition → Asians have highest prevalence of sensitive variants; Africans have lowest.

• Braunwald's Heart Disease, 15th Ed.; Harrison's Principles of Internal Medicine, 22nd Ed.

---

Uses / Indications

• Katzung's Basic and Clinical Pharmacology, 16th Ed.

---

Adverse Drug Reactions

1. Bleeding (Major ADR)

• The most common and serious complication; risk increases with supratherapeutic INR.
• Can occur at any site: GI tract (most common), genitourinary, intracranial (most feared).
• Risk factors: older age, CYP2C9 variants, high INR, concurrent antiplatelet drugs, falls.
• Management of major bleeding:
  • Withhold warfarin.
  • Administer Vitamin K1 (phytomenadione) IV or oral - reverses effect within 12-24 hours.
  • For life-threatening bleeding: 4-factor prothrombin complex concentrate (PCC) for rapid reversal; Fresh Frozen Plasma (FFP) is an alternative.

2. Warfarin-Induced Skin Necrosis

• Rare but serious complication, typically occurring 3-5 days after initiation.
• Caused by a transient hypercoagulable state due to the short half-life of Protein C (natural anticoagulant) being depleted before the procoagulant factors.
• More common in patients with underlying Protein C or S deficiency.
• Characterized by painful skin lesions progressing to necrosis, typically in fat-rich areas (breast, buttocks, thighs, abdomen).

3. Purple Toe Syndrome

• Rare complication (usually within 3-8 weeks of therapy).
• Caused by cholesterol microemboli released from atheromatous plaques, precipitated by anticoagulation.
• Painful, cyanotic discoloration of toes; can progress to gangrene.

4. Teratogenicity

• Warfarin crosses the placenta and is teratogenic, particularly in the first trimester (weeks 6-12).
• Causes warfarin embryopathy: nasal hypoplasia, stippled epiphyses (chondrodysplasia punctata), limb hypoplasia, optic atrophy.
• Second and third trimester exposure: risk of fetal/neonatal bleeding (including intracranial hemorrhage), CNS abnormalities.
• Warfarin is contraindicated in pregnancy (except in some women with mechanical heart valves where the thrombotic risk outweighs fetal risk).

5. Other Adverse Effects

• Alopecia (hair loss)
• Osteoporosis (with long-term use)
• Fatigue, feeling cold
• Braunwald's Heart Disease; Harrison's Principles of Internal Medicine, 22nd Ed.

---

Drug Interactions

Pharmacokinetic Interactions - Increased Effect (↑ INR, ↑ bleeding risk)

Pharmacokinetic Interactions - Decreased Effect (↓ INR, ↓ efficacy)

Pharmacodynamic Interactions - Increased Effect

Pharmacodynamic Interactions - Decreased Effect

• Katzung's Basic and Clinical Pharmacology, 16th Ed.; Braunwald's Heart Disease; Goodman & Gilman's Pharmacological Basis of Therapeutics

---

Key Clinical Points

• Reversal agent: Vitamin K1 (oral: slow reversal in 12-24h; IV: faster). For urgent reversal: 4-factor PCC (preferred) or FFP.
• Start with heparin overlap when treating acute VTE - give both for ≥5 days AND until INR is ≥2.0 on two consecutive readings.
• Avoid in pregnancy (teratogen) - use LMWH instead.
• Narrow therapeutic window - monitor INR regularly; many patients benefit from anticoagulation clinics.
• Food interactions - high vitamin K foods (leafy greens: spinach, kale) can reduce efficacy; patients should maintain a consistent vitamin K intake rather than eliminating it.
• Superseeded for many indications by DOACs (direct oral anticoagulants like rivaroxaban, apixaban, dabigatran), which have fewer interactions, no routine monitoring, and predictable pharmacokinetics - but warfarin remains first-line for mechanical heart valves and in patients with antiphospholipid syndrome.